Table 1.
Characteristics of 135 patients with advanced-stage classic Hodgkin lymphoma and 221 healthy controls
| Patients n = 135 | Controls n = 221 | p value | ||
|---|---|---|---|---|
| Sex, no. (%) | ||||
| Male | 67 | (49.6) | 104 (47.1) | NS |
| Female | 68 | (50.4) | 117 (52.9) | NS |
| Age at diagnosis, mean (range) | 34 | (15–69) | 35 (25–55) | NS |
| Disease subtype, no. (%) | ||||
| Nodular sclerosing | 108 | (80.0) | ||
| Mixed-cellularity | 14 | (10.4) | ||
| Lymphocyte-rich | 9 | (6.7) | ||
| Lymphocyte-depleted | 4 | (2.9) | ||
| Albumin, g/dl, mean (range) | 3.8 | (2.2–5.1) | ||
| Hemoglobin, g/dl, mean (range) | 13.0 | (8.3–14.2) | ||
| Lymphocytes, ×103/μL, mean (range) | 1.75 | (0.3–4.9) | ||
| Neutrophils, ×103/μL, mean (range) | 8.55 | (2.1–35.8) | ||
| Bulky mass, no. (%) | 55 | (40.7) | ||
| “B” symptoms, no. (%) | 73 | (54.1) | ||
| Extranodal extension, no. (%) | 42 | (31.1) | ||
| IPS score ≥ 4 (unfavorable in advanced stages) | 39 | (28.9) | ||
| Ann Arbor stage 1–2a, no. (%) | 0 | (0) | ||
| Stage 2b, no. (%) | 57 | (42.2) | ||
| Stage 3, no. (%) | 45 | (33.3) | ||
| Stage 4, no. (%) | 33 | (24.5) | ||
NS not significant